found that the anti-human APOE antibody HAE-4 (targeting APOE immunotherapy) reduced cerebral amyloid angiopathy and amyloid plaques while improving cerebral vascular function in animal experiments, which provides experimental evidence for immunotherapy for the treatment of Alzheimer’s disease (74). Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.